Phaseline

Targets › MRC1

MRC1 (Macrophage mannose receptor 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Apr 2027.

Mediates the endocytosis of glycoproteins by macrophages. Binds both sulfated and non-sulfated polysaccharide chains.; FUNCTION: (Microbial infection) Acts as a phagocytic receptor for bacteria, fungi and other pathogens.; FUNCTION: (Microbial infection) Acts as a receptor for Dengue virus envelope protein E..; FUNCTION: (Microbial infection) Interacts with Hepatitis B virus envelope protein. (UniProt, P22897)

Open in Phaseline: the race on MRC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Universitair Ziekenhuis Brussel68GaNOTA-Anti-MMR-VHH2
Macrophage Mannose Receptor (MMR) targeting radiotracer for PET imaging
MRC1Phase 2Non-small Cell Lung CancerApr 2027

Conditions

Non-small Cell Lung Cancer (1)

Modalities

small molecule (1)

Companies

Universitair Ziekenhuis Brussel (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.